Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · IEX Real-Time Price · USD
79.02
+0.68 (0.87%)
At close: Dec 5, 2023, 4:00 PM
79.03
+0.01 (0.01%)
After-hours: Dec 5, 2023, 7:55 PM EST
0.87%
Market Cap 97.61B
Revenue (ttm) 27.39B
Net Income (ttm) 5.88B
Shares Out 1.25B
EPS (ttm) 4.66
PE Ratio 16.96
Forward PE 10.31
Dividend $3.00 (3.80%)
Ex-Dividend Date Dec 14, 2023
Volume 6,277,013
Open 78.37
Previous Close 78.34
Day's Range 77.85 - 79.28
52-Week Range 72.87 - 89.74
Beta 0.31
Analysts Buy
Price Target 89.36 (+13.09%)
Earnings Date Nov 7, 2023

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, ... [Read more]

Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,000
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2022, GILD's revenue was $27.28 billion, a decrease of -0.09% compared to the previous year's $27.31 billion. Earnings were $4.59 billion, a decrease of -26.23%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $89.36, which is an increase of 13.09% from the latest price.

Price Target
$89.36
(13.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy®...

5 days ago - Business Wire

J&J, Gilead, BMS: A look at undervalued dividend payers

Johnson & Johnson NYSE: JNJ,  Gilead Sciences Inc. NYSE: GILD and Bristol Myers Squibb Co. NYSE: BMY are among healthcare sector dividend-payers trading at low valuations relative to their earnings.

Other symbols: JNJ
6 days ago - MarketBeat

AHF Protests ‘Greedy Gilead' for Price Gouging

NEW YORK--(BUSINESS WIRE)--AHF Protests ‘Greedy Gilead' for Price Gouging in NYC.

6 days ago - Business Wire

AHF Targets ‘Greedy Gilead' for Price Gouging

MIAMI--(BUSINESS WIRE)--AHF Targets ‘Greedy Gilead' for Price Gouging in Miami.

7 days ago - Business Wire

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expand...

Other symbols: ACLX
20 days ago - Market Watch

Kite and Arcellx Announce Expansion in Strategic Partnership

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing c...

Other symbols: ACLX
20 days ago - Business Wire

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- ...

Other symbols: ACLX
20 days ago - PRNewsWire

WHO's new COVID guidelines see fewer patients requiring hospitalization

Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.

Other symbols: MRKPFE
25 days ago - Market Watch

Buying the dip in high-yield Gilead Sciences

Gilead Sciences NASDAQ: GILD share price tanked following the Q3 release on what was otherwise a good report. The company is gaining traction in key markets, sustaining its core business, and offsetti...

26 days ago - MarketBeat

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca...

27 days ago - Business Wire

AHF Slams Gilead Profiteering

LOS ANGELES--(BUSINESS WIRE)--AHF Slams Gilead Profiteering.

4 weeks ago - Business Wire

Gilead stock rises on top-, bottom-line beats

Gilead Sciences Inc.'s GILD, -0.65% stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. Gilead ...

4 weeks ago - Market Watch

Gilead quarterly results beat Street estimates as profit up on lower taxes

Drugmaker Gilead Sciences on Tuesday said third-quarter sales were little changed from a year earlier, but earnings rose 21% due mainly to lower taxes.

4 weeks ago - Reuters

Gilead Sciences Announces Third Quarter 2023 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023. “Gilead has now delivered two years of c...

4 weeks ago - Business Wire

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemother...

Other symbols: RCUS
4 weeks ago - Business Wire

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemothera...

Other symbols: RCUS
4 weeks ago - Business Wire

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AAS...

4 weeks ago - Business Wire

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral presentations, during the 6...

4 weeks ago - Business Wire

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

SANTA MONICA & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a researc...

5 weeks ago - Business Wire

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new re...

6 weeks ago - Business Wire

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) presented new data today supporting Sunlenca® (lenacapavir) as an important treatment option for adults with multi-drug resis...

6 weeks ago - Business Wire

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy...

6 weeks ago - Business Wire

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option ...

6 weeks ago - Business Wire

Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs

Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with an initial focus in hepatitis B virus and hepatiti...

7 weeks ago - Market Watch

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases.

Other symbols: ASMB
7 weeks ago - Business Wire